Nurtec ODT vs Qulipta: Comparing Oral CGRP Antagonists for Migraine

The most important difference between Nurtec and Qulipta is their approved uses. Nurtec ODT is the only oral CGRP antagonist with dual FDA approval for both acute treatment (taken as needed when a migraine strikes) and preventive treatment (taken regularly to reduce migraine frequency). This means a single medication can serve both purposes.

For acute use, Nurtec 75mg is taken at the onset of a migraine. In the acute trials, 21% of patients were pain-free at 2 hours versus 11% with placebo, and 35% had freedom from their most bothersome symptom at 2 hours. For prevention, it's taken every other day.

Qulipta is approved only for prevention—it cannot be used to treat an active migraine attack. Patients on Qulipta still need a separate acute treatment (like a triptan or Nurtec). This means two medications instead of one, which can be a drawback for both convenience and cost.

For patients with moderate migraine frequency (4–8 days/month) who want simplicity, Nurtec's dual role is a significant advantage. For patients with high-frequency migraine (9+ days/month) who already have an effective acute treatment, Qulipta's daily preventive schedule may provide more consistent CGRP blockade.

Both drugs significantly reduce monthly migraine days (MMD), but their clinical trial designs make direct comparison imperfect:

Qulipta (ADVANCE trial, 60mg): Reduced MMD by 4.2 days versus 2.5 for placebo. The 50% responder rate was 61% (vs 29% placebo). In the PROGRESS trial (chronic migraine), Qulipta 60mg reduced MMD by 7.5 days.

Nurtec (BHV3000-305 trial, 75mg every other day): Reduced MMD by 4.3 days versus 3.5 for placebo. The 50% responder rate was 49% (vs 41% placebo). The smaller placebo-adjusted difference is partly due to a high placebo response rate in this trial.

While head-to-head trials haven't been conducted, Qulipta's continuous daily dosing may provide more consistent CGRP receptor blockade compared to Nurtec's every-other-day schedule. The clinical trial data suggests Qulipta may have a slight edge for prevention specifically, though both are effective. Nurtec's unique value is in its dual acute + preventive utility.

Form and convenience: Nurtec ODT dissolves on the tongue without water—ideal during a migraine when nausea makes swallowing pills difficult. Qulipta is a standard tablet requiring water. For acute use, Nurtec's orally disintegrating form is a meaningful advantage.

Side effects: Nurtec has a notably clean side effect profile—in clinical trials, adverse event rates were barely above placebo (nausea 1.4% vs 1.1% placebo). Qulipta has higher rates of nausea (6–12% depending on dose), constipation (6–9%), and fatigue (4–5%). For side effect tolerance, Nurtec has the edge.

Drug interactions: Both are CYP3A4 substrates. Qulipta requires dose adjustment with strong CYP3A4 inhibitors (e.g., ketoconazole) and should be avoided with strong CYP3A4 inducers. Nurtec should not be taken with strong CYP3A4 inhibitors and requires caution with moderate inhibitors.

Cost: Both are expensive brand-name medications ($800–$1,100/month). Neither has a generic. Both manufacturers offer savings programs that can reduce costs to $0–$10/month for commercially insured patients. Without insurance or savings cards, cost can be prohibitive.